Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Esophageal Squamous Cell Carcinoma 6Leukemia 5Esophageal Neoplasms 5Rectal Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oropharyngeal Neoplasms 2Oligodendroglioma 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, T-Cell 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Carcinoma 2Astrocytoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

atezolizumab 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡